{"nctId":"NCT01031095","briefTitle":"(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)","startDateStruct":{"date":"2009-06"},"conditions":["Coronary Artery Disease"],"count":200,"armGroups":[{"label":"Low dose intracoronary heparin","type":"EXPERIMENTAL","interventionNames":["Other: coronary intervention"]},{"label":"Standard treatment arm","type":"ACTIVE_COMPARATOR","interventionNames":["Other: coronary intervention"]}],"interventions":[{"name":"coronary intervention","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patients; who have planned elective PCI and have had written informed consent for participation to study.\n* The native coronary artery;\n\n  * lesion with narrowing \\>=70%,\n  * lesion without thrombus\n  * no left main coronary artery (LMCA) lesion\n  * no chronic total occlusion lesion\n\nExclusion Criteria:\n\n* Patients have allergy for acetylsalicylic acid (ASA), Clopidogrel and heparin\n* Patients who performed primary PCI\n* Patients with acute coronary syndrome\n* Patients with have a history of myocardial infarction (MI) for two weeks\n* Patients who were use UFH or low molecular weight heparin (LMWH) for 24 hours\n* Patients on warfarin therapy\n* Patients who have bleeding diathesis, or have high risk for bleeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Major Adverse Cardiac Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Major Adverse Cardiac Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":100},"commonTop":[]}}}